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The simultaneous use of many drugs is called polypharmacy, which is known to increase 
as people get older. Polypharmacy is usually defined as the concomitant use of five or 
more drugs. Previous research has shown that polypharmacy increases the risk of drug 
interactions, adverse effects, and often causes problems with patient compliance. In 
addition, it can lead to unnecessary hospitalisation (1-5). 
A clinical decision support system (CDSS), which is a computer program designed to 
support healthcare professionals in clinical decision-making, has already provided a 
feasible solution for a basic form of medication surveillance.  
Medication surveillance, one of the activities carried out by physicians and pharma-
cists to assure safe and beneficial use of drugs, has already been performed since sev-
eral decades by using a first generation CDSS. This first generation CDSS alerts against 
incorrect dosages, drug-drug interactions, and contraindications (drug-disease interac-
tions). The first generation CDSS can nowadays be combined with one of the more ad-
vanced second generation CDSSs that are able to combine information on individual 
patient characteristics such as diagnoses and laboratory values.  
Currently, in addition to the daily (digital) medication surveillance intended to pre-
vent incorrect dosages, drug-drug interactions, and contraindications, (manual) medica-
tion reviews of older adults are performed periodically to ensure optimal pharma-
cotherapy. A ‘medication review’ is defined as a structured evaluation of a patient’s 
medication by a physician and a pharmacist, taking into account both the patient’s med-
ical history and laboratory values (6). In the Netherlands, the Health Care Inspectorate 
(IGZ) expects all residents of nursing homes and homes for the elderly to receive a med-
ication review by a physician and a pharmacist twice a year and yearly, respectively. 
Both processes, medication surveillance and medication reviews, aim for medication 
optimisation, which is the optimal use of medication by taking into account the benefits 
and safety aspects of the drugs used. This thesis has explored the possibilities of using 
an advanced CDSS to automate medication optimisation. 
In the following paragraphs the societal relevance of the thesis will be shown in a 
number of highlighted messages for daily practice, each of which is subsequently ex-
plained in more detail. 
 
The results of this thesis confirm that a more feasible and efficient method is 
essential to fulfil the current IGZ-required medication reviews.  
 
In a survey conducted among pharmacists who provide care for nursing homes and 
residential homes, we have demonstrated that only a part of the medication reviews 
required by the IGZ is actually performed with a minimum performance of 42% and a 
maximum of 76% with respect to the IGZ-requirements. The enormous effort needed to 
comply with the required medication reviews is most probably the cause of this under-
performance.  
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We have shown that in an average pharmacy one pharmacist annually has to work 
full-time for 2.5 months to perform the IGZ required medication reviews. This suggests 
that performing all the medication reviews required by the IGZ is very time consuming 
and costly when performed with the currently available manual methods.  
 
This thesis shows that automation of medication reviews may be useful. The 
study provides practical insight into the aspects that have to be taken into 
consideration and need to be optimised in order to further improve the 
efficiency of these reviews. 
 
Our study indicated that automation of medication reviews can provide efficiency bene-
fits. The idea to automate medication reviews is not new. However, our proposed ap-
proach, which does not require the manual input of individual patient data, e.g. medica-
tion and patients’ characteristics, into the CDSS, followed by automated generation of 
drug related alerts, will most probably lead to a considerable reduction of the review 
time.  
The first step towards the automation of medication reviews by a CDSS was to in-
crease the efficiency of the medication surveillance of an advanced CDSS, which is piv-
otal in reducing alert fatigue and in being able to perform cost-efficient medication 
surveillance. Performing automated medication surveillance with an efficient advanced 
CDSS may already contribute to the optimisation of drug use, and should actually pre-
vent suboptimal drug use that would normally only be identified through manually 
performed medication reviews.  
The ideal advanced CDSS should optimally alert for all clinical relevant drug related 
problems without any false positive alerts, thereby already preventing alert fatigue. 
However, it might be more realistic to aim for a CDSS that alerts for all clinical relevant 
drug related problems of which 80% are clinically relevant.  
The second step in the automation of medication reviews by a CDSS was the devel-
opment of a CDSS with content that actually supports medication reviews, i.e. algo-
rithms to identify drug related problems (DRPs). In the thesis we have described the 
necessary steps for the development of such a CDSS.  
 
This thesis shows that automation of medication reviews by a comprehensive 
CDSS should be further improved by increasing the number of relevant 
algorithms that identify drug related problem. This increase in relevant 
algorithms is necessary to widely implement the CDSS in patient care. 
 
The third step was to explore the value of the newly developed CDSS by comparing the 
performance of manual medication reviews in hospitalized geriatric patients with the 
DRP notifications generated by the CDSS. This comparison showed that the new CDSS 
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was able to support medication reviews by alerting for 10% of newly identified DRPs in 
relation to the DRPs previously identified in the manual medication reviews. However, 
in our study the overall support of the manual medication review remained limited to 
28% of the total of identified DRPs, i.e. DRPs identified by the manual medication review 
and CDSS, thereby revealing that our new CDSS needs to be enhanced. On the other 
hand, the CDSS algorithms that had identified the DRPs, had a sensitivity of 73% and 
specificity of 99%, which is good for an advanced CDSS. Therefore, the CDSS studied is 
in itself already a very efficient tool to augment the first generation CDSS which was 
primarily used for medication surveillance. Furthermore, our study also confirmed that 
the categories identified are relevant for an efficient CDSS that claims to be both feasi-
ble and effective for performing automated medication reviews. Although the new 
CDSS should be further enhanced in order to provide optimal support for medication 
reviews, the DRPs that have already been identified by the CDSS, can even now be easily 
applied on a daily or weekly basis instead of the manual medication reviews performed 
once or twice per year. When the CDSS will be applied more frequently, this will allow 
early prevention and will increase the efficiency of medication reviews. Moreover, the 
already automated parts of the medication review in the CDSS have now been support-
ed by the addition of literature references, thus allowing the healthcare provider to 
estimate the value of the alerts.  
Nevertheless, the limitations of the newly developed CDSS, i.e. undetected DRPs and 
irrelevant alerts, should be solved so that the number of relevant DRPs identified by the 
CDSS can be further increased. In addition, in our study we have characterized DRPs 
that are not easily automated and implemented into a CDSS, i.e. algorithms that initiate 
deprescribing. These DRPs, and the other described limitations, offer a roadmap of 
important issues that should be investigated further to improve the CDSS even more. 
When eventually it will be possible to automate medication reviews to a maximum, this 
will create the possibility to spend more time on the non-automated parts of the medi-
cation review process, such as the consultations between physician, pharmacist, and 
patient.  
 
This thesis has revealed that a CDSS may also be used in the detection of 
patients prone to develop a delirium. 
 
Finally, the use of a CDSS in the prediction of a sub-acute disease was also explored in 
this thesis. In 18 European countries 182 billion US dollars is spent yearly on care for 
delirium patients alone, while 30-40% of the delirium cases might have been prevented 
and delirium diagnoses are often missed (7). Delirium occurs frequently in hospitalised 
older adults, and is associated with increased morbidity and mortality.  
Our study revealed that a CDSS can indeed be used to automatically predict a deliri-
um. Despite the absence of important electronically available risk factors, the devel-
 150 
oped prediction model showed to be already worthwhile with only the electronically 
available delirium risk factors. The absence of important risk factors uncovered the 
limitations of the currently available information in electronic health records. In general 
there is a lack of recorded documentation of relevant patient information in electronic 
health records (8). If this patient information, including relevant risk factors, would be 
available for automation, then the predictive quality of the developed delirium model 
developed during our study would increase even more. 
Furthermore, automated presentation of patients at risk for delirium would be very 
beneficial since it does not seem realistic to assume that every physician has similar 
expertise on high impact diseases such as delirium. Automated prediction models do 
not have to be limited to delirium, but can also be used more widely for other predic-
tion algorithms such as the risk of falling or the risk of neonatal sepsis. In the case of an 
increased risk of falling, additional preventive measures could be initiated in time or 
medication causing the fall risk could be minimised. In the case of the early alerting for 
neonatal sepsis by automated prediction, this has already been shown to decrease 
mortality (9, 10). 
This type of applicability of a CDSS may be very useful in the future to improve pa-
tient care and patient safety, although more research is needed to fully appreciate ad-
vanced CDSSs for the use in the automated prediction of delirium and other relevant 
diseases or care problems.  
  
Valorisation 
151 
REFERENCES 
1.  Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 
2014;13(1):57-65. 
2.  Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E et al. Adverse drug events in ambulatory 
care. N Engl J Med. 2003;348(16):1556-64. 
3.  Tsai KT, Chen JH, Wen CJ, Kuo HK, Lu IS, Chiu LS et al. Medication adherence among geriatric outpatients 
prescribed multiple medications. Am J Geriatr Pharmacother. 2012;10(1):61-8. 
4.  Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckler M et al. Risk factors for adverse drug events 
among nursing home residents. Arch Intern Med. 2001;161(13):1629-34. 
5.  Nobili A, Pasina L, Tettamanti M, Lucca U, Riva E, Marzona I et al. Potentially severe drug interactions in 
elderly outpatients: results of an observational study of an administrative prescription database. J Clin 
Pharm Ther. 2009;34(4):377-86. 
6.  Zermansky A, Petty D, Raynor T, Lowe C, Freemantle N. Clinical medication review by a pharmacist of 
patients on repeat prescriptions in general practice: a randomised controlled trial. Health Technol Assess. 
2002;6(20):86. 
7.  Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-22. 
8.  Hope C, Estrada N, Weir C, Teng CC, Damal K, Sauer BC. Documentation of delirium in the VA electronic 
health record. BMC Res Notes. 2014;7:208. 
9.  Fairchild KD. Predictive monitoring for early detection of sepsis in neonatal ICU patients. Curr Opin 
Pediatr. 2013;25(2):172-9. 
10.  Deschamps T, Le Goff CG, Berrut G, Cornu C, Mignardot J-B. A decision model to predict the risk of the 
first fall onset. Exp Gerontol. 2016;81:51-5. 
 
  
